[Pharmacological profile and clinical findings of fesoterodine (Toviaz®Tablets )].
Masanori
M
Hizue
Yasuo
Y
Ochi
Miki
M
Imura
Hideomi
H
Yamagami
D000818:Animals; D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D018721:Muscarinic Agonists / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009928:Organ Specificity; D017060:Patient Satisfaction; D011788:Quality of Life; D051381:Rats; D011976:Receptors, Muscarinic; D013607:Tablets; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology / Q000523:psychology; D014563:Urodynamics / Q000187:drug effects*; D064804:Urological Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*
D001559:Benzhydryl Compounds; D018721:Muscarinic Agonists; D011976:Receptors, Muscarinic; D013607:Tablets; D064804:Urological Agents; C526675:fesoterodine